I emailed the CSO of US Stem Cell, Kristin Comella, for any reaction to today’s big news of the DOJ filing suit against two stem cell clinic firms including hers seeking injunctions. I also emailed the leaders of the other firm, California Stem Cell Treatment Center/Cell Surgical Network. It’s important to include the clinic firms’ […]
Responses From Both US Stem Cell & Cell Surgical Network to DOJ Action Read More »
The last few years for the publicly-traded stem cell clinic biz, US Stem Cell, Inc., which goes by the ticker $USRM, have seemed like a rollercoaster to me as an observer. I can see four main areas of news that to me make the future seem uncertain for this firm. First, the US Stem was linked to the
Clinic biz US Stem Cell reports SEC subpoena, adding to uncertainty on its future Read More »
There are now so many clinics selling non-FDA approved stem cell offerings across the U.S. that tens or hundreds of thousands of patients are at risk. How did we get here? What if we had a way of understanding how stem cell clinics spread across the U.S. in the first place? For example, an animated
Animated map video shows wildfire spread of US stem cell clinics lacking FDA approval Read More »
The ability of for-profit stem cell clinics to pitch unproven, risky stem cell offerings to patients may soon get much tougher in Australia. The country’s Therapeutic Goods Administration (TGA), which has some similar responsibilities there as the FDA does here in the U.S., announced planned new reforms that’ll put stem cell clinics under more scrutiny and more
Australia takes big step to curtail dangerous stem cell clinics Read More »
Can a stem cell clinic business get FDA RMAT designation? At least one announced it was trying, but now seems to have given up. Stem cell clinic business US Stem Cell, Inc. has reportedly announced that it is at least temporarily abandoning its efforts at getting Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The
US Stem Cell bid for FDA RMAT rejected? Read More »
Do three blinded US Stem Cell clinic patients with major or complete vision loss constitute a significant adverse outcome? I would say so and a new paper details how this happened apparently at a particular publically-traded South Florida stem cell clinic business. You can see the damaged retinas of one such patient below in an image
NEJM paper links 3 blinded patients to US Stem Cell clinic Read More »
The stem cell clinic business US Stem Cell Inc., formerly known as Bioheart, has seen its stock take a rollercoaster ride recently include a big run up and now today a big drop so what’s the scoop? US Stem Cell, which includes a few subsidiaries such as US Stem Cell Clinic, focuses on the use
What’s the deal with US Stem Cell Inc stock? Read More »
A brief report in the NEJM today highlights the risks facing patients who get stem cell treatment from dubious clinics as one such patient recently developed a large spinal tumor. Dr. Aaron L. Berkowitz and colleagues describe how this patient who received a mixture of several stem cell types from an overseas clinic was later diagnosed
Patient gets cancer growing on spine from dubious stem cell treatment Read More »
A team of researchers from Sun Yat-sen University in China and here in California at my graduate alma mater UCSD has published a remarkable, new report in Nature reporting human lens regeneration in cataracts. This is a truly amazing idea that endogenous stem cells can regrow new lenses. I wonder if we are on a path to someday
Eureka: Endogenous Stem Cells Regrow New Lens for Cataracts Read More »
Last month the stem cell community learned that a patient of the business US Stem Cell Inc./US Stem Cell Clinic, previously known as Bioheart, had filed suit in a Broward County Florida Court against the publicly traded company alleging various charges including damage to her eye. Now US Stem Cell has more recently filed suit in the
US Stem Cell Clinic sues anonymous critics for libel, seeks IDs from websites Read More »